Glaukos (GKOS) Q2 Revenue Jumps 30%

(NYSE:GKOS), a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of $124.1 million, beating analyst expectations of $115.5 million by 7.4%. Non-GAAP earnings per share (EPS) came in at a loss of ($0.24), outperforming the anticipated ($0.26) non-GAAP loss. Both top-line and bottom-line results showed sharp improvements over the same period last year. The quarter was marked by ongoing strong adoption of its innovative glaucoma products in the U.S. and continued expansion in global markets.

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.

Glaukos develops and commercializes innovative therapies for chronic eye diseases, including glaucoma, corneal disorders, and retinal diseases. Its leading treatments include micro-invasive glaucoma surgery (MIGS) devices, pharmaceutical implants, and therapies aimed at improving patient outcomes with less invasive approaches.

Continue reading

Source Fool.com